Skip to main content

Table 1 Patient and disease characteristics

From: Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

Patient characteristics RIC MAC p value
Number of patients 271 425  
Recipient age at SCT (years, range) 53 (18–76) 38 (18–74) <10−4
Recipient age (by classes), n (%)    <0.0001
 < 30 46 (17.0 %) 148 (34.8 %)  
 30–40 32 (11.8 %) 82 (19.3 %)  
 40–50 45 (16.6 %) 98 (23.1 %)  
 ≥ 50 148 (54.6 %) 97 (22.8 %)  
Recipient gender, n (%)    0.42
 Male 153 (56.5 %) 252 (59.6 %)  
 Female 118 (43.5 %) 171 (40.4 %)  
Year of SCT (median), year (%) 2010 2011 0.65
 2001–2007 23 (8.5 %) 74 (17.4 %) <0.0001
 2008–2012 248 (91.5 %) 351 (82.6 %)
Interval from diagnosis to SCT (days, range) 299 (52–3892) 272 (41–3689) 0.24
Donor age 37 years (19–71) 42 years (12–70) 0.83
Donor age (by classes), year (%)    0.55
 < 30 39 (29.3 %) 54 (29.2 %)  
 30–40 32 (24.1 %) 33 (17.8 %)  
 40–50 29 (21.8 %) 46 (24.9 %)  
 ≥ 50 33 (24.8 %) 52 (28.1 %)  
Donor gender, n (%)    0.69
 Male 138 (50.9 %) 223 (52.5 %)  
 Female 133 (49.1 %) 202 (47.5 %)  
Female donor to male recipient, n (%) 76 (28 %) 119 (28.1 %) 0.98
Diagnosis, n (%)    <0.0001
 AML 217 (80.1 %) 286 (67.3 %)  
  Good cytogenetics 8 (6 %) 19 (14 %)
  Intermediate cytogenetics 47 (37 %) 53 (39 %)  
  Poor cytogenetics 19 (15 %) 18 (13 %)  
  Secondary AML 54 (42 %) 45 (33 %)  
  Missing cytogenetics 89 (41 %) 151 (53 %)  
 ALL 54 (19.9 %) 139 (32.7 %)
  Phi+ ALL 15 (54 %) 27 (36 %)
  Missing cytogenetics 26 (48 %) 64 (46 %)  
Disease status at SCT, n (%)    <0.0001
 CR1 78 (28.8 %) 175 (41.2 %)  
 ≥ CR2 67 (24.7 %) 118 (27.8 %)  
 Active disease 126 (46.5 %) 132 (31.1 %)  
Karnosky at SCT, n (%)    0.05
 ≤ 80 % 101 (39.9 %) 109 (32 %)  
 > 80 % 152 (60.1 %) 232 (68 %)  
 Missing 18 (6.7 %) 84 (19.8 %)  
Patient positive CMV serology, n (%) 213 (79.8 %) 311 (78.3 %) 0.66
CMV risk, n (%)    0.06
 Low 35 (13.3 %) 59 (15.2 %)  
 Intermediate 169 (64.2 %) 272 (69.3 %)  
 High 59 (22.4 %) 56 (14.5 %)  
  1. AML acute myeloid leukemia, ALL acute lymphoid leukemia, CMV cytomegalovirus, CMV risk low = negative recipient and donor serology, high positive recipient and negative donor serology, intermediate all other combinations, CR complete remission, SCT stem cell transplantation